SC 13G/A: TELA Bio, Inc.
Ticker: TELA · Form: SC 13G/A · Filed: Oct 28, 2024 · CIK: 1561921
| Field | Detail |
|---|---|
| Company | Tela Bio, Inc. (TELA) |
| Form Type | SC 13G/A |
| Filed Date | Oct 28, 2024 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g-a
AI Summary
SC 13G/A filing by TELA Bio, Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G/A filing submitted by Tela Bio, Inc. (ticker: TELA) to the SEC on Oct 28, 2024.
What is the risk level of this SC 13G/A filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti).
How long is this filing?
Tela Bio, Inc.'s SC 13G/A filing is 7 pages with approximately 1,963 words. Estimated reading time is 8 minutes.
Where can I view the full SC 13G/A filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,963 words · 8 min read · ~7 pages · Grade level 7.2 · Accepted 2024-10-28 16:06:51
Key Financial Figures
- $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti
Filing Documents
- d856443dsc13ga.htm (SC 13G/A) — 82KB
- 0001193125-24-245498.txt ( ) — 84KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Date: October 28, 2024 EW HEALTHCARE PARTNERS FUND 2, L.P. By: /s/ Martin P. Sutter Name: Martin P. Sutter Title: Managing Director EW HEALTHCARE PARTNERS FUND 2-A, L.P. By: /s/ Martin P. Sutter Name: Martin P. Sutter Title: Managing Director EW HEALTHCARE PARTNERS FUND 2-UGP, LLC By: /s/ Martin P. Sutter Name: Martin P. Sutter Title: Managing Director EW HEALTHCARE PARTNERS FUND 2 GP, L.P. By: /s/ Martin P. Sutter Name: Martin P. Sutter Title: Managing Director JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13G relating to the Common Stock of TELA Bio, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13G/A will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, and (iii) the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934 apply to each of them. This agreement may be terminated with respect to the obligations to jointly file future amendments to such This Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Date: October 28, 2024 EW HEALTHCARE PARTNERS FUND 2, L.P. By: /s/ Martin P. Sutter Name: Martin P. Sutter Title: Managing Director EW HEALTHCARE PARTNERS FUND 2-A, L.P. By: /s/ Martin P. Sutter Name: Martin P. Sutter Title: Managing Director EW HEALTHCARE PARTNERS FUND 2-UGP, LLC By: /s/ Martin P